SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors

The cyclin-dependent kinase 4/6 (CDK4/6) kinase is dysregulated in melanoma, highlighting it as a potential therapeutic target. CDK4/6 inhibitors are being evaluated in trials for melanoma and additional cancers. While beneficial, resistance to therapy is a concern, and the molecular mechanisms of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Akihiro, Bu, Yiwen, Qie, Shuo, Wrangle, John, Camp, E. Ramsay, Hazard, E. Starr, Hardiman, Gary, de Leeuw, Renée, Knudsen, Karen E., Diehl, J. Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750908/
https://www.ncbi.nlm.nih.gov/pubmed/31555743
http://dx.doi.org/10.1126/sciadv.aax6352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750908/
https://www.ncbi.nlm.nih.gov/pubmed/31555743
http://dx.doi.org/10.1126/sciadv.aax6352

Ejemplares similares